We have recently demonstrated that incorporation of costimulatory signaling domains, such as CD137 (4-1BB), CD28 or CD27, into a αFR-specific CAR overcomes the limitations of past CAR approaches by improving the persistence and anti-tumor activity of transferred CAR T cells in vivo [19, 20]. The gene discussed is TNFRSF9; the disease is neoplasm.